At Anveta Therapeutics, we didn’t arrive at NCE development by accident. We arrived here because of a 50-year journey that the entire Indian pharma industry has been on and because we believe the most consequential chapter of that journey is just beginning.
India’s pharmaceutical journey is one of resilience, ambition, and transformation.
The Early Foundations (1970s–1980s)
India built its base in generics and bulk drugs, ensuring access and affordability worldwide. At a time when much of the developing world lacked essential medicines, Indian pharma stepped in as a reliable, cost-efficient supplier — laying the groundwork for what would become a globally significant industry.
Global Expansion (1990s–2000s)
Indian companies became global suppliers, exporting generics and APIs at scale. Regulatory approvals in the US, Europe, and beyond validated Indian manufacturing standards and cemented the country’s reputation as the world’s pharmacy.
Innovation & Growth (2010s–Present)
The focus shifted toward discovery, clinical research, and regulatory approvals: laying the groundwork for India’s rise as an innovation hub. Investment in R&D, academic-industry collaboration, and a maturing clinical trial ecosystem began to change the nature of what Indian pharma could produce, not just manufacture.
Today, India Is Entering a New Era: Defined by NCEs
The momentum is no longer a projection. It is visible in the milestones:
- Wockhardt – Zaynich FDA Approval (May 2026): A fully Indian-originated NCE receiving FDA approval: a landmark that would have seemed improbable a decade ago.
- Zydus Lifesciences – Saroglitazar NDA Approval (2026): A novel molecule addressing metabolic disease, moving through the US regulatory pathway on the strength of Indian discovery science.
- AbbVie & Ichnos/Glenmark Innovation – Global Licensing Agreement (2025): A first-in-class trispecific antibody, ISB-2001, licensed globally: signalling that India’s innovation contribution now extends beyond small molecules into cutting-edge biologics.
- Lupin – $25M AbbVie Milestone (2023): A significant validation of Lupin’s MALT1 inhibitor NCE program, with a global pharma giant placing a meaningful bet on Indian-originated science.
Each of these milestones is more than a headline. Together, they signal India’s shift from being the world’s pharmacy to becoming a true engine of innovation: where discovery, development, and regulatory success converge to shape the future of global healthcare.
Where Anveta TX Fits and What We’re Building
At Anveta, we see India as a launchpad for breakthrough therapies. Our mission is to rigorously evaluate and advance NCEs with speed, efficiency, and uncompromising quality. By leveraging India’s scientific talent and infrastructure, we aim to deliver therapies that are both groundbreaking and globally relevant.
Our Collaboration Model
We believe the future of drug discovery lies in partnerships. Academia, biotech startups, and global pharma leaders must work together to unlock innovation at the pace the world needs.
Our co-development model is built on a principle of scientific continuity: enabling the originating researchers who discovered a target or mechanism to remain actively engaged as programs advance from discovery through IND-enabling studies and into early clinical development. Shared risk, shared reward, and shared scientific ownership are not just commercial terms for us: they define how we think about building lasting partnerships.
An Invitation
We invite academic researchers, biotech collaborators, co-development partners, and strategic investors to be part of this next chapter in Indian pharma’s evolution.
India is not just rising: it is reshaping the future of drug discovery. At Anveta, we are proud to stand at the forefront of this transformation.
- Anand Bokare
- anand.bokare@anvetatx.com